Buserelin Acetate (Suprefact®)

Buserelin Acetate (SuCommon name: Buserelin Acetate
Brand name: Suprefact®


What is Buserelin Acetate?

Buserelin Acetate is a luteinizing hormone releasing hormone (LHRH) analogue that is used in the palliative treatment of advanced (metastatic) prostate cancer. Buserelin acetate works by blocking the production of testosterone which reduces the growth and reproduction of prostate cancer cells.
 

How is Buserelin Acetate administered?

Buserelin Acetate is by administered by subcutaneous injection or as a nasal solution.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received buserelin acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Diarrhea
  • Dizziness
  • Dry mouth
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Reduced sexual desire (low libido)


Is Buserelin Acetate covered in my province or territory?*

Buserelin acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
  • Nunavut
  • Northwest Territories
  • Yukon
Buserelin acetate is not covered by provincial drug programs in:
  • Prince Edward Island


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=6447


    
Last Reviewed: July 2017

 
   
   

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive